Prime Medicine, Inc. (NASDAQ:PRME - Get Free Report)'s share price traded down 7.6% during mid-day trading on Tuesday. The company traded as low as $3.90 and last traded at $3.8710. Approximately 3,077,519 shares changed hands during mid-day trading, a decline of 9% from the average session volume of 3,391,353 shares. The stock had previously closed at $4.19.
Analyst Ratings Changes
Several research firms have commented on PRME. Jefferies Financial Group reaffirmed a "market outperform" rating on shares of Prime Medicine in a report on Monday, September 28th. Chardan Capital reiterated a "buy" rating and issued a $7.00 target price on shares of Prime Medicine in a research note on Friday, September 25th. Wall Street Zen raised shares of Prime Medicine from a "sell" rating to a "hold" rating in a research report on Saturday, October 31st. Citigroup restated a "market outperform" rating on shares of Prime Medicine in a research note on Friday, September 25th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $8.00 price objective on shares of Prime Medicine in a report on Monday. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $7.86.
Check Out Our Latest Stock Analysis on PRME
Prime Medicine Stock Down 8.4%
The company has a market capitalization of $696.50 million, a PE ratio of -4.00 and a beta of 2.14. The company has a 50-day moving average price of $3.71 and a two-hundred day moving average price of $3.51.
Prime Medicine (NASDAQ:PRME - Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. Prime Medicine had a negative return on equity of 222.88% and a negative net margin of 2,497.56%. The business had revenue of $4.21 million for the quarter. As a group, equities analysts anticipate that Prime Medicine, Inc. will post -0.97 EPS for the current fiscal year.
Institutional Investors Weigh In On Prime Medicine
Several hedge funds and other institutional investors have recently modified their holdings of PRME. Arizona State Retirement System boosted its position in shares of Prime Medicine by 15.5% in the second quarter. Arizona State Retirement System now owns 28,646 shares of the company's stock valued at $106,000 after acquiring an additional 3,855 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Prime Medicine by 15.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 33,094 shares of the company's stock worth $102,000 after acquiring an additional 4,349 shares during the period. Royal Bank of Canada increased its holdings in Prime Medicine by 89.3% during the 1st quarter. Royal Bank of Canada now owns 9,254 shares of the company's stock worth $32,000 after acquiring an additional 4,365 shares during the period. Swiss National Bank lifted its stake in Prime Medicine by 5.0% in the 1st quarter. Swiss National Bank now owns 178,600 shares of the company's stock worth $622,000 after purchasing an additional 8,500 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Prime Medicine in the 3rd quarter worth approximately $28,000. 70.37% of the stock is currently owned by institutional investors.
Prime Medicine Company Profile
(
Get Free Report)
Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Prime Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.
While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.